by Truveta Research | May 11, 2023 | News
Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena, MD, PhD and Christopher M Worsham, MD, MPH from Harvard University, the new research...
by Truveta staff | Apr 20, 2023 | News
Truveta is a healthcare company that is passionate about improving patient care and saving lives by harnessing the transformative potential of EHR data and artificial intelligence (AI). In a recent article from Microsoft that highlighted our vision and mission, “How...
by Terry Myerson, CEO | Apr 12, 2023 | News
UPDATE: Truveta has won the 2024 South by Southwest (SXSW) Innovation Award in Artificial Intelligence for its AI-enabled health research and the Truveta Language Model (TLM). Healthcare data traditionally has been siloed, inaccessible, and too messy to be useful for...
by Truveta staff | Mar 22, 2023 | News
Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
by Terry Myerson, CEO | Mar 1, 2023 | News
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
by Truveta staff | Feb 15, 2023 | News
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
